AUS
NZ
UK
CA
USA
IND
Summary
- HEXO Corp’s 10-day average volume is 2.2 million units. The stock has been ranked among TMX’s Top Healthcare stocks that are outperforming their peers in the last 30 days.
- Neptune Wellness Solutions’ stock has recovered 82.85 per cent since the pandemic-led market crash in March.
- Valens reported net revenue of C$ 18.1 million for its Q3 FY20, a 10 per cent increase year-over-year.
- Shares of Delta 9 Cannabis have swelled by 37.77 per cent in the last six months.
The earnings season is here, and many cannabis companies have started posting their results. Some have posted stellar financial reports, while others still seem to be struggling. The S&P/TSX Cannabis Index is trading flat this year and is up over six per cent quarter-to-date.
Let’s have a look at HEXO Corp. (TSX:HEXO), Neptune Wellness Solutions Inc. (TSX:NEPT), The Valens Company Inc. (TSX:VLNS), and Delta 9 Cannabis Inc. (TSX:DN) and their latest stock performance and financial health.
HEXO Corp. (TSX:HEXO)
Current Stock Price: C$ 0.81
Pot stock Hexo has rebounded by 55.76 per cent since the pandemic-led market crash on March 19.
In the last six months, the stock has surged by 14.08 per cent. However, the stock has plunged by 59.5 per cent in its year-to-date performance.
Quebec-based HEXO Corp creates and distributes consumer packaged cannabis products to serve the worldwide cannabis market. It operates through its hub and spoke business strategy and collaborating with Fortune 500 companies to strengthen the use of technology and create a more viable distribution network.
As per TMX data, the company’s 10-day average volume is 2.2 million units. The stock has been ranked among TMX’s Top Healthcare stocks that are outperforming their peers across the TSX and the TSXV. The company’s current market capitalization stands at C$ 391.59 million, and its price-to-book (P/B) ratio is 0.704.
HEXO Corp. reported net revenue of C$ 27.1 million for its Q4 FY20, a growth of 76 per cent from Q4 FY19. The company posted a gross profit of C$ 26.953 million in Q4 FY20, an increase of 26.27 percent compared to C$ 21.344 million in Q4 FY19.
Neptune Wellness Solutions Inc. (TSX:NEPT)
Current Stock Price: C$ 2.56
Neptune Wellness develops legal cannabis and hemp with the help of research and development and business centered on the use of cannabinoids for health and wellness. The company also provides supply chain solutions in the healthcare sector.
The stock shows a drop of 24.26 per cent in its year-to-date performance. As per data on the TMX website, the company’s current market capitalization stands at C$ 329.63 million, and its price-to-book (P/B) ratio is 2.098.
However, the stock has recovered 82.85 per cent since the pandemic-led market crash.
Last week, the company announced that its innovations unit has entered into a letter of credit facility with Perceptive Advisors to offer the company up to US$45 million to aid the fulfillment of large orders received from a customer.
The company reported total revenue of C$ 21.363 million for the first quarter fiscal 2021 ended June 30, 2020, representing an increase of 390 per cent, compared to C$ 4.361 million for Q1 FY20.
The company posted a gross profit of C$ 3.256 million in Q1 FY21, an increase of C$ 3.969 million over Q1 FY20.
The Valens Company Inc. (TSX:VLNS)
Current Stock Price: C$ 1.62
The Valens Company stock has tumbled by 50.9 per cent year-to-date.
The firm develops and produces cannabinoid-based goods, specializing in its extraction methods such as CO2, ethanol, hydrocarbon, solvent-less, and terpene. The company earns most of its revenue from the cannabis business.
On March 19, the stock fell to C$1.85 due to the pandemic-led market crash. Since then, the stock has further declined by 12.43 per cent.
In the last six months, the stock has declined by over 25 per cent.
As per TMX data, the company’s current market capitalization is C$ 207.9 million, and its price-to-book (P/B) ratio is 1.473.
Valens reported net revenue of C$ 18.1 million for its Q3 FY20, an increase of 10 per cent compared to C$ 16.5 million in Q3 FY19. The company’s gross profit amounted to C$ 7.313 million in Q3 FY20, a decline of nearly 42.9 percent compared to C$ 12.807 million in Q3 FY19.
Delta 9 Cannabis Inc. (TSX:DN)
Current Stock Price: C$ 0.62
Delta 9 Cannabis Inc engages in biotechnology and medical research. The company produces licensed medical marijuana and operates a Manitoba-based production facility. It develops three varieties of cannabis – Indica, Sativa, and Hybrid.
In the last six months, the stock has swelled by 37.77 per cent. The stock has rebounded 63.15 per cent since the pandemic-led market crash on March 19. However, the stock is down 7.46 per cent in its year-to-date.
As per TMX data, the company’s 10-day average volume is 2.2 million units. Delta 9 Cannabis has been placed among TMX’s Top Healthcare stocks that have the largest price gains in the last 30 days. The company’s current market capitalization stands at C$ 55.3 million, and its price-to-book (P/B) ratio is 4.76. The company provides positive return on equity (ROE) and return on assets (ROA) at 3.65 per cent and 2.05 per cent, respectively.
Delta 9 reported net revenue of C$ 13.0 million for the second quarter of 2020, a growth of 46 per cent compared to C$ 8.9 million for Q2 FY19. The company registered a gross profit of $4.6 million for Q2 FY20, an increase of 57 per cent, compared to C$ 2.9 million for the same quarter last fiscal year.
